Genetic ablation and pharmaceutical inhibition of ACAT1/SOAT1 have been reported to reduce CE, ameliorate AD-associated pathological hallmarks, and attenuate neuroinflammation via modulating toll-like receptor 4 (TLR4) [23,24,25,26,27,28,29,30]. Here, TLR4 is linked to Alzheimer disease.